Implementation Science and the Optimization of HIV Care: What’s All the Buzz About?

Assessment of Needs

Implementation science is an innovative approach to clinical research that identifies and addresses obstacles and facilitators to the uptake of evidence-based clinical innovations. This webinar addresses how implementation science has been utilized to address inequities in access to care, particularly for the clinical use of preexposure prophylaxis (PrEP) to prevent HIV infection in at-risk patient populations.

Learning Objectives

On completion of this activity, learners will be able to:

• Describe how implementation science is being used to optimize care for people with HIV and other infectious diseases
• Explain how implementation science informs population-level strategies for disseminating HIV preexposure prophylaxis (PrEP)

Registration

Who Should Attend

This webinar is designed for clinical decision-makers who are actively involved in HIV care and research, including physicians, physician assistants, nursing professionals, and other health care professionals.

Individual registration is required in order to receive CME credit or a certificate of participation.

Registration closes on Tuesday, May 14, 2024, 10:30 AM (PT).

For more information or questions, please contact the registration department at registration@iasusa.org or 415-544-9400.

Conflicts of Interest

In the interest of maintaining the independence of its continuing medical education (CME) activities, the International Antiviral Society–USA (IAS–USA) requires all persons with control of educational content (eg, faculty, Scientific Leadership Board, Governance Board, and program planner) to disclose any financial relationships with ineligible companies (previously defined as “commercial interests”) that they have had within the past 24 months. Any real or apparent conflicts of interest of those parties are resolved and mitigated prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in IAS–USA CME activities.  

The Accreditation Council for Continuing Medical Education (ACCME) defines ineligible companies as “those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.” 

IAS–USA will identify and resolve ahead of time any possible conflicts of interest that may influence CME activities with regard to exposition or conclusion. Information about financial relationships with ineligible companies for the presenter and planners/reviewers is below and in the slides prior to the presentation of educational content.

Presenter

Dr Okeke reported no relevant financial relationships with ineligible companies. (Updated March 1, 2024)

Moderator

Dr Eaton reported receiving consulting fees from Gilead Sciences. (Updated March 1, 2024)

Planner/Reviewer

Planner/Reviewer 1 reported no relevant financial relationships with ineligible companies (Updated February 6, 2024)

Planner/Reviewer 2 reported no relevant financial relationships with ineligible companies (Updated February 6, 2024)

COW Board

The financial relationships of the COW Board can be found here: https://www.iasusa.org/activities/cases-on-the-web/about-cows/cow-webinars-editorial-board/